ATAndréa Teixeira-Carvalho

Andréa Teixeira-Carvalho

*This is an algorithmically generated author record based on publicly available information.

Andréa Teixeira-Carvalho has a total of 207 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of a yellow fever vaccine model using data from primary vaccination in children and adults, re-vaccination and dose-response in adults and studies with immunocompromised individuals

    by Collaborative Group for Studies of Yellow Fever Vaccine, Carla Rezende Barbosa Bonin, Guilherme Côrtes Fernandes, Reinaldo de Menezes Martins, Luiz Antonio Bastos Camacho, Andréa Teixeira-Carvalho, Licia Maria Henrique da Mota, Sheila Maria Barbosa de Lima, Ana Carolina Campi-Azevedo, Olindo Assis Martins-Filho, et al.

    Background: An effective yellow fever (YF) vaccine has been available since 1937. Nevertheless, questions regarding its use remain poorly understood, such as the ideal dose to confer immunity against the disease, the need for a booster dose, the optimal immunisation schedule for immunocompetent, immunosuppressed, and pediatric populations, among other issues. This work aims to demonstrate that computational tools can be used to simulate different scenarios regarding YF vaccination and the immune response of individuals to this vaccine, thus assisting the response of some of these open questions. Results: This work presents the computational results obtained by a mathematical model of the human immune response to vaccination against YF. Five scenarios were simulated: primovaccination in adults and children, booster dose in adult individuals, vaccination of individuals with autoimmune diseases under immunomodulatory therapy, and the immune response to different vaccine doses. Where data were available, the model was able to quantitatively replicate the levels of antibodies obtained experimentally. In addition, for those scenarios where data were not available, it was possible to qualitatively reproduce the immune response behaviours described in the literature. Conclusions: Our simulations show that the minimum dose to confer immunity against YF is half of the reference dose. The results also suggest that immunological immaturity in children limits the induction and persistence of long-lived plasma cells are related to the antibody decay observed experimentally. Finally, the decay observed in the antibody level after ten years suggests that a booster dose is necessary to keep immunity against YF.


  • Open Access

    Systemic immune mediators predict therapeutic response and tumor-infiltrating lymphocyte intensity in triple-negative breast cancer

    by Ananda D. Lopes, Nayane A.L. Galdino, Amanda B. Figueiredo, Rafael C. Brianese, Katia L.P. Morais, Marina De Brot, Cynthia A.B.T, Osório, Andrea Teixeira-Carvalho, Vinicius F. Calsavara, et al.

    Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer defined by the lack of expression of estrogen receptor, progesterone receptors, and of the human epithelial growth factor receptor 2. Neoadjuvant chemotherapy has proven efficacy in the treatment of TNBC, and a pathological complete response (pCR) is predictive of improved long-term survival. The immune response exerts a vital role in response to neoadjuvant chemotherapy, as indicated by the relation between the percentage of stromal tumor-infiltrating lymphocytes (TILs) in pre-treated tumor tissue samples and the likelihood of achieving pCR. Despite this, the relationship between the systemic immune response and the tumor microenvironment is unclear. In this prospective study, we determined the systemic plasma immune profile of TNBC patients before treatment using a panel of 27 immune mediators and measured the percentage of TILs from the same patients. Patients who demonstrated pCR had significantly higher systemic immune mediators; GM-CSF, FGF-basic, VEGF, IL-2, and IL-5, than the non-responders. Moreover, responders displayed a strong positive correlation between the cytokines IFN-γ and IL-7 with the percentage of TILs, while non-responders had a negative or no correlation. Finally, systemic immune mediator levels before treatment predict pCR (AUC range 0.64 - 0.71), and the combination of immune mediators and TILs improved pCR prediction (AUC 0.71 - 0.82). In conclusion, increased systemic immune mediators reflect increased TILs percentage and act as potential predictive biomarkers of pCR for TNBC patients submitted to neoadjuvant chemotherapy.

  • Systemic Immunological changes in patients with distinct clinical outcomes during Mycobacterium tuberculosis infection

    by Tatiane Figueiredo Morais-Papini, Jordana Grazziela Alves Coelho-Dos-Reis, Ana Paula Barbosa Wendling, Lis Ribeiro Do Vale Antonelli, Pryscilla Fanini Wowk, Vânia Luiza Deperon Bonato, Valéria Maria Augusto, Silvana Elói-Santos, Olindo Assis Martins-Filho, Cláudia Martins Carneiro, et al.


  • Multiple inflammatory markers and 15-year incident ADL disability in admixed older adults: The Bambui-Epigen Study

    by Maria Fernanda Lima-Costa, Juliana V.M. Mambrini, Karen C.L. Torres, Sérgio V. Peixoto, Fabíola B. Andrade, Cesar De Oliveira, Eduardo Tarazona-Santos, Andrea Teixeira-Carvalho, Olindo A. Martins-Filho


  • Flow cytometric-based protocols for assessing anti-MT-2 IgG1 reactivity: High-dimensional data handling to define predictors for clinical follow-up of Human T-cell Leukemia virus type-1 infection

    by Jordana Grazziela Coelho-Dos-Reis, Vanessa Peruhype-Magalhães, Marcelo Antônio Pascoal-Xavier, Matheus de Souza Gomes, Laurence Rodrigues Do Amaral, Ludmila Melo Cardoso, Juan Jonathan-Gonçalves, Ágata Lopes Ribeiro, Ana Lúcia Borges Starling, João Gabriel Ribas, et al.


  • Strategies for serum chemokine/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases

    by Erica Godinho Menezes, Jordana Grazziela Alves Coelho-Dos-Reis, Ludmila Melo Cardoso, Ágata Lopes-Ribeiro, Juan Jonathan-Gonçalves, Marco Túlio Porto Gonçalves, Rodrigo Dias Cambraia, Eric Bassetti Soares, Luciana Diniz Silva, Vanessa Peruhype-Magalhães, et al.


  • Open Access

    Immune response pattern in recurrent Plasmodium vivax malaria

    by Yury Oliveira Chaves, Allyson Guimarães da Costa, Marcelo Luís Monteiro Pereira, Marcus Vinícius Guimarães de Lacerda, Jordana Grazziela Coelho-Dos-Reis, Olindo Assis Martins-Filho, Andréa Teixeira-Carvalho, Adriana Malheiro, Wuelton Marcelo Monteiro, Patrícia Puccinelli Orlandi, et al.

    Plasmodium vivax is the causative agent of human malaria of large geographic distribution, with 35 million cases annually. In Brazil, it is the most prevalent species, being responsible by around 70 % of the malaria cases. A cross-sectional study was performed in Manaus (Amazonas, Brazil), including 36 adult patients with primary malaria, 19 with recurrent malaria, and 20 endemic controls. The ex vivo phenotypic features of circulating leukocyte subsets (CD4+ T-cells, CD8+ T-cells, NK, NKT, B, B1 and Treg cells) as well as the plasmatic cytokine profile (IL-2, IL-4, IL-6, IL-10, TNF and IFN-γ) were assessed, aiming at establishing patterns of immune response characteristic of primary malaria vs recurrent malaria as compared to endemic controls. The proportion of subjects with high levels of WBC was reduced in malaria patients as compared to the endemic control. Monocytes were diminished particularly in patients with primary malaria. The proportion of subjects with high levels of all lymphocyte subsets was decreased in all malaria groups, regardless their clinical status. Decreased proportion of subjects with high levels of CD4+ and CD8+ T-cells was found especially in the group of patients with recurrent malaria. Data analysis indicated significant increase in the proportion of the subjects with high plasmatic cytokine levels in both malaria groups, characterizing a typical cytokine storm. Recurrent malaria patients displayed the highest plasmatic IL-10 levels, that correlated directly with the CD4+/CD8+ T-cells ratio and the number of malaria episodes. The findings confirm that the infection by the P. vivax causes a decrease in peripheral blood lymphocyte subsets, which is intensified in the cases of “recurrent malaria”. The unbalanced CD4+/CD8+ T-cells ratio, as well as increased IL-10 levels were correlated with the number of recurrent malaria episodes. These results suggest that the gradual remodelling of the immune response is dependent on the repeated exposure to the parasite, which involves a strict control of the immune response mediated by the CD4+/CD8+ T-cell unbalance and exacerbated IL-10 secretion.


  • Open Access

    Cross-reactivity of commercially available anti-human monoclonal antibodies with canine cytokines: establishment of a reliable panel to detect the functional profile of peripheral blood lymphocytes by intracytoplasmic staining

    by Marcela L. Moreira, Elaine M. S. Dorneles, Rodrigo P. Soares, Camila P. Magalhães, Christiane Costa-Pereira, Andrey P. Lage, Andréa Teixeira-Carvalho, Olindo A. Martins-Filho, Márcio S. S. Araújo

    Background: The process for obtaining monoclonal antibodies against a specific antigen is very laborious, involves sophisticated technologies and it is not available in most research laboratories. Considering that most cytokines remain partially conserved among species during evolution, the search for antibody cross-reactivity is an important strategy for immunological studies in veterinary medicine. In this context, the amino acid sequence from human and canine cytokines have demonstrated 49–96 % homology, suggesting high probability of cross-reactivity amongst monoclonal antibodies. For this, 17 commercially available anti-human monoclonal antibodies [IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8 (#1, #2), IL-10, IL-12, IL-13, IL-17A, IFN-γ (#1, #2), TNF-α (#1, #2) and TGF-β], were evaluated in vitro for intracellular cytokine detection in a stimulated canine blood culture by flow cytometry and confocal microscopy. Lymphocytes from peripheral blood of healthy and two unhealthy dogs were analyzed. Results: Eleven anti-human mAbs [IL-1α, IL-4, IL-5, IL-6, IL-8 (#1, #2), IL-12, IL-17A, TNF-α (#1, #2) and TGF-β] cross-reacted against canine intracellular cytokines. The specificity of the assays was not affected after Fc-blocking. Three anti-human cytokine mAbs [IL-4, IL-8 (#2) and TGF-β] when evaluated by confocal microscopy also cross-reacted with intracellular canine cytokines. The identification of human mAbs that cross-reacted with canine cytokines may support their use as immunological biomarkers in veterinary medicine studies. Conclusion: The identification of these 11 anti-human cytokine mAbs that cross-reacted with canine cytokines will be useful immunological biomarkers for pathological conditions by flow cytometry and fluorescence microscopy in dogs.


  • Open Access

    FC-TRIPLEX Chagas/Leish IgG1: A Multiplexed Flow Cytometry Method for Differential Serological Diagnosis of Chagas Disease and Leishmaniasis

    by Andréa Teixeira-Carvalho, Fernanda Magalhães Freire Campos, Stefan Geiger, Roberta Dias Rodrigues Rocha, Fernanda Fortes De Araújo, Danielle Marquete Vitelli-Avelar, Mariléia Chaves Andrade, Márcio Sobreira Silva Araújo, Elenice Moreira Lemos, Anna Bárbara De Freitas Carneiro Proietti, et al.

    Differential serological diagnosis of Chagas disease and leishmaniasis is difficult owing to cross-reactivity resulting from the fact that the parasites that cause these pathologies share antigenic epitopes. Even with optimized serological assays that use parasite-specific recombinant antigens, inconclusive test results continue to be a problem. Therefore, new serological tests with high sensitivity and specificity are needed. In the present work, we developed and evaluated the performance of a new flow cytometric serological method, referred to as FC-TRIPLEX Chagas/Leish IgG1, for the all-in-one classification of inconclusive tests. The method uses antigens for the detection of visceral leishmaniasis, localized cutaneous leishmaniasis, and Chagas disease and is based on an inverted detuned algorithm for analysis of anti-Trypanosomatidae IgG1 reactivity. First, parasites were label with fluorescein isothiocyanate or Alexa Fluor 647 at various concentrations. Then serum samples were serially diluted, the dilutions were incubated with suspensions of mixed labeled parasites, and flow cytometric measurements were performed to determine percentages of positive fluorescent parasites. Using the new method, we obtained correct results for 76 of 80 analyzed serum samples (95% overall performance), underscoring the outstanding performance of the method. Moreover, we found that the fluorescently labeled parasite suspensions were stable during storage at room temperature, 4°C, and –20°C for 1 year. In addition, two different lots of parasite suspensions showed equivalent antigen recognition; that is, the two lots showed equivalent categorical segregation of anti-Trypanosomatidae IgG1 reactivity at selected serum dilutions. In conclusion, we have developed a sensitive and selective method for differential diagnosis of Chagas disease, visceral leishmaniasis, and localized cutaneous leishmaniasis.


  • Open Access

    Subdoses of 17DD yellow fever vaccine elicit equivalent virological/immunological kinetics timeline

    by Ana Carolina Campi-Azevedo, Paula de Almeida Estevam, Jordana Grazziela Coelho-Dos-Reis, Vanessa Peruhype-Magalhães, Gabriela Villela-Rezende, Patrícia Flávia Quaresma, Maria de Lourdes Sousa Maia, Roberto Henrique Guedes Farias, Luiz Antonio Bastos Camacho, Marcos da Silva Freire, et al.

    The live attenuated 17DD Yellow Fever vaccine is one of the most successful prophylactic interventions for controlling disease expansion ever designed and utilized in larger scale. However, increase on worldwide vaccine demands and manufacturing restrictions urge for more detailed dose sparing studies. The establishment of complementary biomarkers in addition to PRNT and Viremia could support a secure decision-making regarding the use of 17DD YF vaccine subdoses. The present work aimed at comparing the serum chemokine and cytokine kinetics triggered by five subdoses of 17DD YF Vaccine.